Advertisement
Advertisement
U.S. markets open in 9 hours 7 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Silk Road Medical, Inc (SILK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
49.20+1.06 (+2.20%)
At close: 04:00PM EDT
48.81 -0.39 (-0.79%)
After hours: 05:54PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close48.14
Open47.25
Bid48.81 x 1800
Ask49.59 x 1000
Day's Range47.25 - 49.47
52 Week Range27.21 - 67.49
Volume274,485
Avg. Volume321,804
Market Cap1.734B
Beta (5Y Monthly)1.48
PE Ratio (TTM)N/A
EPS (TTM)-1.60
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.80
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SILK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Silk Road Medical, Inc.
    Analyst Report: Silk Road Medical IncBased in Sunnyvale, California, Silk Road Medical is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR combines the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat carotid artery blockages that may cause strokes. The TCAR procedure involves threading a balloon catheter into the carotid artery from an incision near the groin to expand the narrowed artery. In parallel with the catheter procedure, another device is deployed to temporarily reverse blood flow to the brain in the treated artery in order to prevent any broken off clots from moving to the brain.
    Rating
    Fair Value
    Economic Moat
    28 days agoArgus Research
View more
  • Benzinga

    Silk Road Medical's Q2 Margins Hit By Manufacturing Expansion Costs

    Silk Road Medical Inc (NASDAQ: SILK) posted Q2 revenue of $33.2 million, an increase of 25% Y/Y, driven primarily by increased TCAR adoption, beating the consensus of $31.16 million. "We expanded our FDA label and Medicare coverage for the use of TCAR in standard surgical risk patients, formally initiated our ROADSTER 3 post approval study, and secured access to a $250 million debt facility," said Erica Rogers, CEO "We also gained meaningful market share through strong physician utilization as w

  • Zacks

    Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates

    Silk Road Medical (SILK) delivered earnings and revenue surprises of 6.38% and 6.91%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Silk Road Medical Reports Second Quarter 2022 Financial Results

    SUNNYVALE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended June 30, 2022. “We achieved several important milestones in the second quarter. We expanded our FDA label and Medicare coverage for the use of TCAR in standard surgical risk patients, formally initiated our ROADSTER 3 post approval study, and secured access to a $250 mi

Advertisement
Advertisement